Dr. Kimberly Driscoll’s Publications

Contributions to T1D science focus on the following areas. Listing of Dr. Driscoll’s published work can be found here.

Adherence to the type 1 diabetes regimen has been a major interest of mine since beginning my academic position. The technology associated with the T1D regimen is extremely unique as the data can be downloaded from devices including blood and continuous glucose monitors and insulin pumps so that adherence behaviors can be evaluated objectively, as opposed to relying on subjective, patient self-report. To this end, I am one of very few clinical researchers who use these downloaded data and one of even fewer clinical researchers who use the data to evaluate adherence behaviors in relation to other factors (e.g., psychological).

  1. Driscoll KA, Johnson SB, Tang Y, Yang F, Deeb LC, Silverstein J. (2011). Does blood glucose monitoring increase prior to clinic visits in children with type 1 diabetes? Diabetes Care, 34, 2170-2173.
  2. Driscoll, K.A., Wang, Y., Johnson, S.B., Gill, E., Lynch, R., Stephens, H., Willbur, K., Wright, N., & Deeb, L.C. (2016). White coat adherence in pediatric insulin pump users. Journal of Diabetes Science and Technology, 9, 646-652.
  3. Driscoll, K.A., Wang, Y., Johnson, S.B., Gill, E., Wright, N., & Deeb, L.C. (2017). White coat adherence occurs in adolescents with type 1 diabetes receiving intervention to improve insulin pump adherence behaviors. Journal of Diabetes Science and Technology, 11, 455-460.
  4. Patton, S.R., Driscoll, K.A., Clements, M. (2017). Adherence to insulin pump behaviors in young children with type 1 diabetes mellitus: Opportunities for intervention. Journal of Diabetes Science and Technology, 11, 87-91.
  5. Driscoll, K.A., Wang, Y., Johnson, S.B., Wright, N. & Deeb, L.C. (2019). Blood glucose monitoring before and after type 1 diabetes clinic visits. Journal of Pediatric Psychology, 44, 32-29.

Diabetes technology is an essential part of the treatment regimen and it is rapidly evolving. Although diabetes technology is necessary, it is not sufficient to achieve optimal glycemic control as measured by time in range or A1C. As a behavioral scientist, I am interested in human behavior and acceptance and satisfaction with devices, which are the rate limiting factors associated with optimizing the use of sophisticated diabetes technologies.

  1. Forlenza, G.P., Messer, L.H., Berget, C., Wadwa, R.P., Driscoll, K.A. (2018). Biopsychosocial factors associated with satisfaction and sustained use of artificial pancreas technology and its components: A call to the technology field. Current Diabetes Reports. 18, 114.
  2. Berget, C., Driscoll, K.A., Lagges, A., Lange, S., DiMeglio, L.A., Hannon, T.S., Woerner, S.E., Iturralde, E., Barley, R.C., Hanes, S., Hood, K.K., Buckingham, B.B. (2019). Optimizing the use of continuous glucose monitoring in young children with type 1 diabetes with an adaptive study design and multiple randomizations. Contemporary Clinical Trials, 82, 60-65.
  3. Messer, L H., Cook, P., Tanenbaum, M.L., Hanes, S., Driscoll, K.A., Hood, K.K. (2019). CGM Benefits and Burdens: Two brief measures of continuous glucose monitoring. Journal of Diabetes Science & Technology, 13, 1135-114.
  4. Messer, L.H., Berget, C., Vigers, T., Pyle, L., Geno, C., Wadwa, R.P., Driscoll, K.A., & Forlenza, G. P. (2020). Real world hybrid closed-loop discontinuation: Predictors and perceptions of youth discontinuing the 670G system in the first 6 months. Pediatric Diabetes, 21, 319-327.
  5. Berget, C., Messer, L.H., Vigers, T., Frohnert, B., Pyle, L., Wadwa, R.P., Driscoll, K.A., & Forlenza, G. P. (2020). Six months of hybrid closed loop in the real-world: An evaluation of children and young adults using the 670G system. Pediatric Diabetes, 21, 310-318.
  6. Messer, L.H., Tanenbaum, M.L., Cook, P.F., Wong, J.J., Hanes, S.J., Driscoll, K.A., Hood, K.K. (in press). Cost, hassle, and on-body experience: Barriers to diabetes device use in adolescents and potential intervention targets. Diabetes Technologies and Therapeutics.

As a clinical psychologist, I am interested in the psychosocial aspects of T1D management because although sophisticated technologies exist and will be further developed in the future (e.g., artificial pancreas), they can only be optimized if the patients who use these devices have the knowledge and skills to use them properly which can be negatively and positively impacted by psychological factors (e.g., anxiety).

  1. Driscoll, K.A., Volkening, L., Haro, H., Ocean, G., Wang, Y., Crismond Jackson, C., Clogherty, M., Hale, D.E., Klingensmith, G.J., Laffel, L., Deeb, L.C., & Siminerio, L.M. (2015). Are children with type 1 diabetes safe at school? Examining parent perceptions. Pediatric Diabetes, 16, 613-620.
  2. Majidi, S., Driscoll, K.A., & Raymond, J. (2015). Anxiety in children and adolescents with type 1 diabetes. Current Diabetes Reports, 15, 47.
  3. Driscoll, K.A., Corbin, K.D., Maahs, D.M., Pratley, R., Bishop, F.K., Kahkoska, A., Hood, K.K., Mayer-Davis, E. (2017). Biopsychosocial aspects of weight management in type 1 diabetes: A review and next steps. Current Diabetes Reports, 17, 28.
  4. Driscoll, K.A., Raymond, J., Naranjo, D., & Patton, S.R. (2016). Fear of hypoglycemia in children and adolescents and their parents with type 1 diabetes. Current Diabetes Reports, 16, 1-9.
  5. Kahkoska, A.R., Watts, M.E., Driscoll, K.A., Bishop, F.K., Mihas, P., Thomas, J., Law, J.R., Jain, N., & Mayer-Davis, E.J. (2018). Understanding antagonism and synergism: A qualitative assessment of weight management in youth with type 1 diabetes. Obesity Medicine, 9, 21-31.
  6. Corbin, K.D., Driscoll, K.A., Pratley, R.E., Smith, S.R., Maahs, D.M., Mayer-Davis, E.J. on behalf of Advancing Care for Type 1 Diabetes and Obesity Network (ACT1ON). (2018). Obesity in Type 1 Diabetes: Pathophysiology, Clinical Impact and Mechanisms. Endocrine Reviews, 39, 629-663.
  7. O’Donnell, H.K., Berget, C., Wooldridge, J., Driscoll, K.A. (2019). Graduated exposure to treat fear of hypoglycemia in a young adult with type 1 diabetes: A case study. Pediatric Diabetes, 20, 113-118.
  8. Majidi, S., O’Donnell, H.K., Stanek, K., Youngkin, E., Gomer, T., Driscoll, K.A. (2020). Suicide risk assessment in youth and young adults with type 1 diabetes. Diabetes Care, 43, 343-348.
  9. Bispham, J.A., Hughes, A.S., Driscoll, K.A., McAuliffe-Fogarty, A.H. (2020). Novel challenges in aging with type 1 diabetes. Current Diabetes Reports, 20, 15.

Combining my interests in adherence to the type 1 diabetes treatment regimen and the psychosocial aspects that impact T1D adherence, I have built a line of research aimed at providing intervention to improve both.

  1. Bishop, F.K., Driscoll, K.A., Hunter, C.M., Kichler, J., Maahs, D.M., Seid, M., Standiford, D., Thomas, J., Mayer-Davis, E.J. (2016). The Flexible Lifestyle 3mpowering Change (FL3X) clinical trial: Recruitment and retention strategies. Pediatric Diabetes, 17(S24), 90.
  2. Driscoll, K.A., Johnson, S.B., Wang, Y., Wright, N., Deeb, L.C. (2016). Providing patient-friendly data improves insulin pump adherence. Pediatric Diabetes, 17(S24), 50.
  3. Patton, S.R., Driscoll, K.A., Clements, M. (2017). Adherence to insulin pump behaviors in young children with type 1 diabetes mellitus: Opportunities for intervention. Journal of Diabetes Science and Technology, 11, 87-91.
  4. Kichler, J.C., Seid, M., Crandell, J., Maahs, D.M., Bishop, F.K., Driscoll, K.A., Standiford, D., Hunter, C.M., & Mayer-Davis, E. (2018). The Flexible Lifestyle Empowering Change (FLEX) Intervention for self-management in adolescents with Type 1 Diabetes: Trial design and baseline characteristics. Contemporary Clinical Trials, 66, 64-73.